Compare Stocks

Date Range: 

 United TherapeuticsMaravai LifeSciencesJazz PharmaceuticalsBridgeBio PharmaMirati Therapeutics
SymbolNASDAQ:UTHRNASDAQ:MRVINASDAQ:JAZZNASDAQ:BBIONASDAQ:MRTX
Price Information
Current Price$195.42$37.15$174.59$48.03$144.00
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.71.62.12.01.6
Analysis Score3.51.53.44.53.3
Community Score2.24.43.42.52.9
Dividend Score0.00.00.00.00.0
Ownership Score1.70.01.72.51.7
Earnings & Valuation Score1.31.91.90.60.0
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$227.14$38.13$192.63$71.67$226.46
% Upside from Price Target16.23% upside2.62% upside10.33% upside49.21% upside57.26% upside
Trade Information
Market Cap$8.75 billion$9.57 billion$9.93 billion$7.17 billion$7.39 billion
Beta0.52N/A1.080.821.64
Average Volume368,1091,399,009738,564949,774487,705
Sales & Book Value
Annual Revenue$1.45 billionN/A$2.16 billion$40.56 million$3.34 million
Price / Sales6.04N/A4.60176.772,213.03
CashflowN/AN/A$23.79 per shareN/AN/A
Price / CashN/AN/A7.34N/AN/A
Book Value$63.36 per shareN/A$54.99 per share$3.83 per share$9.67 per share
Price / Book3.08N/A3.1712.5414.89
Profitability
Net Income$-104,500,000.00N/A$523.37 million$-260,590,000.00$-213,260,000.00
EPS($2.39)N/A$14.60($2.48)($5.69)
Trailing P/E Ratio18.490.0055.08N/AN/A
Forward P/E Ratio16.8662.9711.42N/AN/A
P/E GrowthN/AN/A4.64N/AN/A
Net Margins33.25%N/A7.86%N/AN/A
Return on Equity (ROE)15.48%N/A20.16%-109.88%-60.01%
Return on Assets (ROA)11.31%N/A10.85%-48.54%-54.21%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.24%N/A0.55%2.19%N/A
Current Ratio7.22%N/A3.98%9.85%8.84%
Quick Ratio6.88%N/A3.84%9.85%8.84%
Ownership Information
Institutional Ownership Percentage90.09%N/A95.67%95.53%94.92%
Insider Ownership Percentage10.90%N/A4.60%40.32%4.10%
Miscellaneous
Employees9504101,940385199
Shares Outstanding44.80 million257.62 million56.90 million149.28 million51.33 million
Next Earnings Date8/4/2021 (Estimated)5/10/2021 (Confirmed)8/3/2021 (Estimated)8/10/2021 (Estimated)8/5/2021 (Estimated)
OptionableOptionableNot OptionableOptionableNot OptionableOptionable
SourceHeadline
Leerink Partners Stick to Their Buy Rating for Mirati TherapeuticsLeerink Partners Stick to Their Buy Rating for Mirati Therapeutics
investing.com - May 9 at 9:38 AM
Mirati: Q1 Earnings Snapshot | Raleigh News & ObserverMirati: Q1 Earnings Snapshot | Raleigh News & Observer
newsobserver.com - May 6 at 7:45 PM
Mirati Therapeutics Reports First Quarter 2021 Financial Results and Recent Corporate UpdatesMirati Therapeutics Reports First Quarter 2021 Financial Results and Recent Corporate Updates
markets.businessinsider.com - May 6 at 7:45 PM
Were Hedge Funds Right About Piling Into Mirati Therapeutics (MRTX)?Were Hedge Funds Right About Piling Into Mirati Therapeutics (MRTX)?
finance.yahoo.com - May 4 at 12:35 PM
Mirati Therapeutics, Inc. (NASDAQ:MRTX) Expected to Post Earnings of -$2.13 Per ShareMirati Therapeutics, Inc. (NASDAQ:MRTX) Expected to Post Earnings of -$2.13 Per Share
americanbankingnews.com - May 2 at 6:14 PM
Pre-earnings Momentum Trade With a Technical Trigger in Mirati Therapeutics IncPre-earnings Momentum Trade With a Technical Trigger in Mirati Therapeutics Inc
cmlviz.com - April 24 at 6:43 PM
Thinking Of Buying Mirati Therapeutics, Inc. (NASDAQ:MRTX) Stock? Read This FirstThinking Of Buying Mirati Therapeutics, Inc. (NASDAQ:MRTX) Stock? Read This First
stocksregister.com - April 24 at 1:43 PM
Mirati to contribute $4 million grant to support SU2C research on KRAS mutant cancersMirati to contribute $4 million grant to support SU2C research on KRAS mutant cancers
news-medical.net - April 19 at 2:22 PM
$4 million grant from Mirati Therapeutics to support SU2C research on KRAS mutant cancers$4 million grant from Mirati Therapeutics to support SU2C research on KRAS mutant cancers
eurekalert.org - April 19 at 9:22 AM
Stand Up To Cancer Announces $4 Million Grant From Mirati Therapeutics To Support Research On KRAS Mutant CancersStand Up To Cancer Announces $4 Million Grant From Mirati Therapeutics To Support Research On KRAS Mutant Cancers
prnewswire.com - April 19 at 9:22 AM
Mirati Therapeutics Inc (MRTX): Price Now Near $156.54; Daily Chart Shows Downtrend on 100 Day BasisMirati Therapeutics Inc (MRTX): Price Now Near $156.54; Daily Chart Shows Downtrend on 100 Day Basis
etfdailynews.com - April 13 at 2:19 PM
Mirati Therapeutics Presents Preclinical Data on Novel Approach to PRMT5 Inhibition that Selectively Targets the PRMT5/MTA Complex in MTAP-Deleted Cancer ModelsMirati Therapeutics Presents Preclinical Data on Novel Approach to PRMT5 Inhibition that Selectively Targets the PRMT5/MTA Complex in MTAP-Deleted Cancer Models
markets.businessinsider.com - April 10 at 5:07 PM
Mirati Therapeutics Inc (MRTX): Price Now Near $180.94; Daily Chart Shows Downtrend on 50 Day BasisMirati Therapeutics Inc (MRTX): Price Now Near $180.94; Daily Chart Shows Downtrend on 50 Day Basis
etfdailynews.com - April 1 at 12:54 PM
Is Mirati Therapeutics (MRTX) Stock A Buy or Sell?Is Mirati Therapeutics (MRTX) Stock A Buy or Sell?
finance.yahoo.com - March 23 at 1:42 PM
Mirati Therapeutics Inc (MRTX): Price Now Near $179.53; Daily Chart Shows Downtrend on 100 Day BasisMirati Therapeutics Inc (MRTX): Price Now Near $179.53; Daily Chart Shows Downtrend on 100 Day Basis
etfdailynews.com - March 22 at 11:59 AM
Mirati Therapeutics, Inc. (26M.F)Mirati Therapeutics, Inc. (26M.F)
ca.finance.yahoo.com - March 20 at 9:46 AM
7 Pharmaceutical Stocks Working on Their Next Blockbuster7 Pharmaceutical Stocks Working on Their Next Blockbuster
markets.businessinsider.com - March 12 at 4:54 PM
MRTX Mar 2021 195.000 callMRTX Mar 2021 195.000 call
au.finance.yahoo.com - March 7 at 1:33 PM
Mirati: 4Q Earnings Snapshot | Raleigh News & ObserverMirati: 4Q Earnings Snapshot | Raleigh News & Observer
newsobserver.com - February 25 at 10:27 PM
Mirati Therapeutics Reports Fourth Quarter And Full-Year 2020 Financial Results And Recent Corporate UpdatesMirati Therapeutics Reports Fourth Quarter And Full-Year 2020 Financial Results And Recent Corporate Updates
markets.businessinsider.com - February 25 at 5:26 PM
Why Turning Point Is Turning HeadsWhy Turning Point Is Turning Heads
msn.com - February 23 at 12:42 PM
Mirati Therapeutics To Present At Upcoming Healthcare ConferencesMirati Therapeutics To Present At Upcoming Healthcare Conferences
finance.yahoo.com - February 18 at 5:01 PM
MD Anderson and Mirati Therapeutics collaborate to expand evaluation of potent KRAS inhibitorsMD Anderson and Mirati Therapeutics collaborate to expand evaluation of potent KRAS inhibitors
news-medical.net - February 10 at 11:03 AM
Mirati allies with MD Anderson to run KRAS clinical trialsMirati allies with MD Anderson to run KRAS clinical trials
fiercebiotech.com - February 10 at 11:03 AM
Mirati Therapeutics To Present At Guggenheim Healthcare Talks 2021 Oncology DaysMirati Therapeutics To Present At Guggenheim Healthcare Talks 2021 Oncology Days
finance.yahoo.com - February 4 at 5:00 PM
DateCompanyBrokerageAction
5/6/2021United TherapeuticsHC WainwrightBoost Price Target
4/14/2021United TherapeuticsJPMorgan Chase & Co.Boost Price Target
3/1/2021United TherapeuticsCredit Suisse GroupBoost Price Target
2/25/2021United TherapeuticsWedbushBoost Price Target
2/16/2021United TherapeuticsOppenheimerBoost Price Target
1/20/2021United TherapeuticsCowenBoost Price Target
1/20/2021United TherapeuticsLADENBURG THALM/SH SHBoost Price Target
3/10/2020United TherapeuticsJefferies Financial GroupUpgrade
3/9/2021Maravai LifeSciencesKeyCorpBoost Price Target
3/9/2021Maravai LifeSciencesMorgan StanleyBoost Price Target
12/15/2020Maravai LifeSciencesStifel NicolausInitiated Coverage
12/15/2020Maravai LifeSciencesWilliam BlairInitiated Coverage
12/15/2020Maravai LifeSciencesThe Goldman Sachs GroupInitiated Coverage
12/15/2020Maravai LifeSciencesBank of AmericaInitiated Coverage
12/15/2020Maravai LifeSciencesRobert W. BairdInitiated Coverage
12/14/2020Maravai LifeSciencesUBS GroupInitiated Coverage
5/9/2021Jazz PharmaceuticalsSVB LeerinkReiterated Rating
4/21/2021Jazz PharmaceuticalsCantor FitzgeraldBoost Price Target
3/2/2021Jazz PharmaceuticalsPiper SandlerBoost Price Target
11/3/2020Jazz PharmaceuticalsWells Fargo & CompanyBoost Price Target
11/3/2020Jazz PharmaceuticalsRoyal Bank of CanadaBoost Price Target
11/3/2020Jazz PharmaceuticalsBarclaysBoost Price Target
3/20/2021BridgeBio PharmaMizuhoInitiated Coverage
12/14/2020BridgeBio PharmaBTIG ResearchBoost Price Target
10/6/2020BridgeBio PharmaBMO Capital MarketsBoost Price Target
12/8/2020Mirati TherapeuticsEvercore ISIInitiated Coverage
12/8/2020Mirati TherapeuticsJMP SecuritiesInitiated Coverage
11/10/2020Mirati TherapeuticsGuggenheimDowngrade
10/8/2020Mirati TherapeuticsCSFBBoost Price Target
(Data available from 5/10/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.